Suitable preclinical models such as patient-derived xenografts (PDX) are needed to evaluate drugs specifically targeting prostate cancer and have historically been difficult to generate due to the benign nature of this disease and the difficulty in propagating the model. Despite these challenges, Crown Bioscience offers a collection of prostate cancer PDX models featuring tumor material diagnosed based on operative pathology and immunohistochemistry (IHC) focused on prostate specific markers e.g. PSA and androgen receptor expression. More
PDX offer the most translational preclinical model for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, PDX models reflect the heterogeneity and diversity of the human patient population. PDX give you an accurate, predictive model of how your treatment will perform, well before entering into expensive clinical trials. Crown Bioscience’s HuPrime® PDX models are well characterized for pathology, growth characteristics, and are also genetically/genomically annotated for gene expression, gene copy number, mutations, and fusions.